Synsam Group’s Q3 report 2024
Reading Time: 5 minutes Continued organic growth by consistent strategy execution 1 July – 30 September 2024 Net sales increased to SEK 1,559 million (1,450), up 7.6 percent. Organic growth totalled 9.5 percent (7.0) Net sales from spectacles subscriptions increased 11.0 percent (13.7) The gross
Guidewire Outlines Vision for How Modern Core Platforms will Unlock a New Era of Efficiency and Effectiveness in P&C Insurance
Reading Time: 6 minutes Nashville, Tenn., United States: CONNECTIONS CONFERENCE – Guidewire (NYSE: GWRE) will showcase its commitment to improving risk selection and pricing, indemnity management, and claims efficiency in property and casualty insurance at its annual customer conference, Connections. The event will unveil future
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization
Reading Time: 3 minutes Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, today releases its third quarter 2024 results. Lytix achieved substantial progress in its clinical pipeline, progressing towards
New Esri Book Explores How Spatial Data Science Helps Users Understand Data and Make Predictions
Reading Time: 3 minutes Redlands, Calif., United States: Esri, the global leader in geographic information system (GIS) software, has released Spatial Data Science, a new book thatdemonstrates how spatial scientists and practitioners can add big data into their workflows and methods. The book shows how
Novotech Releases Comprehensive Report on the Global Clinical Trial Landscape for Small Cell Lung Cancer (SCLC)
Reading Time: 2 minutes San Francisco, United States: Novotech, the global full-service clinical Contract Research Organization (CRO), has published a new report, Small Cell Lung Cancer: Global Clinical Trial Landscape 2024, providing an in-depth analysis of current trends, challenges, and opportunities in SCLC clinical trials
HistoSonics® Enrolls First Patients in Company’s Novel BOOMBOX Master Study
Reading Time: 4 minutes MINNEAPOLIS, United States: HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients were enrolled in their novel prospective master protocol study, called BOOMBOX, designed to evaluate the real-world use of histotripsy for treatment of liver
Kährs confirms that the redemption of its outstanding senior secured sustainability linked floating rate bonds 2021/2026 with ISIN SE0017085285 is no longer conditional
Reading Time: 2 minutes Kährs BondCo AB (publ) (the “Company“) hereby refers to its senior secured sustainability linked floating rate bonds 2021/2026 with ISIN SE0017085285 (the “Bonds“) and to the terms and conditions of the Bonds (the “Terms and Conditions“). Reference is further made to
Fondia Plc: Share repurchase 18.11.2024
Reading Time: < 1 minute Fondia Plc Company release 18.11.2024 at 6.45 p.m. EET Fondia – Acquisition of own shares 18.11.2024 Fondia Plc First North Finland Date 18.11.2024 Exchange transactions Buy Share class FONDIA Amount, shares 160 Average price/share, EUR 6,00
#24-395 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
#24-396 Delisting of Derivatives from NGM
Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market